The Kable

The Kable

Share this post

The Kable
The Kable
💊 Indian-made cough syrups under WHO scrutiny; Global Fund falls short of target; More than drugs needed for diabetes
Copy link
Facebook
Email
Notes
More

💊 Indian-made cough syrups under WHO scrutiny; Global Fund falls short of target; More than drugs needed for diabetes

#188 | The African Medical Centre takes shape

Vinod's avatar
Vinod
Oct 06, 2022
∙ Paid

Share this post

The Kable
The Kable
💊 Indian-made cough syrups under WHO scrutiny; Global Fund falls short of target; More than drugs needed for diabetes
Copy link
Facebook
Email
Notes
More
Share

Hello and welcome back to The Kable in what has been an eventful week for launches, but not necessarily of the good kind.

In response to South Korea and the US launching missiles yesterday in response to North Korea launching missiles the day before, now North Korea has launched two more missiles today, saying its recent missile tests are necessary countermeasures against joint military drills by the two countries. Phew, that was a mouthful of a sentence, but you try clubbing so many launches into one.

In separate - and obviously unrelated - news, the US is stocking up on radiation sickness drugs, coughing up (no pun intended) $290 million to Amgen for its blood disorder med Nplate. The drug is approved to treat blood cell injuries linked to acute radiation syndrome (ARS) in kids and adults.

In The Netherlands, authorities are asking poultry farmers to impose a curfew on the social lives of their birds because bird flu. Across Europe, a combination of disease (bird flu and swine flu, most prominently) and weather (heat, drought, wildfires, rains, floods) have resulted in lower meat and dairy production so far this year. The prognosis does not look so good for the rest of the year, either.

Speaking of Europe, government offices in France are bracing for an extra-cold winter this year. The government won't supply hot water to any public offices in an energy-saving measure.

Keep reading with a 7-day free trial

Subscribe to The Kable to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 The Kable
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More